BofA Securities downgraded Talis Biomedical from Neutral to Underperform and set a new price target of $3.00

JP Morgan downgraded Talis Biomedical from Neutral to Underweight and set a new price target of $7.00 from $10.00 previously

BTIG Research downgraded Talis Biomedical from Buy to Neutral

Piper Sandler downgraded Talis Biomedical from Overweight to Neutral and set a new price target of $9.00

JP Morgan downgraded Talis Biomedical from Overweight to Neutral and set a new price target of $10.00 from $17.00 previously

Piper Sandler initiated coverage of Talis Biomedical with a rating of Overweight and set a new price target of $17.00

Bank of America initiated coverage of Talis Biomedical with a rating of Neutral and set a new price target of $14.00

JPMorgan Chase & Co. initiated coverage of Talis Biomedical with a rating of Overweight and set a new price target of $18.00

BTIG Research initiated coverage of Talis Biomedical with a rating of Buy and set a new price target of $18.00

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a

REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. Recent Business Highlights Initiated clinical study to support COVID-19 510(k) submission for clearance of the Talis One® systemPresented positive data at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) annual meeting differentiating the planned Talis One test menu Development-stage chlamy

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platf

Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a molecular point-of-care (POC) test system with time to result in less than 30 minutes Ability to effectively lyse challenging fungal pathogens, including Candida, in under four minutes on Talis One® system positions Company to develop POC vaginal infection panel REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels. Results from these studies, presented in poster sessions at the 2023 IDSOG Annual Meeting in Denver, Colorado, support Ta

REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In order to regain compliance, the Company's common stock was required to maintain a closing bid price of at l

REDWOOD CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will effect a 1-for-15 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Reverse Stock Split"), effective at 5:00 p.m. Eastern time on July 5, 2023 (the "Effective Time"). The Company's common stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on July 6, 2023. At the Company's ann

REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director. "Heiner's entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is

REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced a business update and reported financial results for the first quarter ended March 31, 2023. Business Update Established ability to manufacture cartridges and instruments that puts us on a path to meaningful margins at scale, at the pace and quality needed to execute the company's business strategyPrioritized development of four Talis One® test panels to address significant unmet needs in the w

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical's w

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platf

REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director. "Heiner's entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that Rob Kelley, the Company's current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately. Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters. About Rob KelleyMr. Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Company's Chief Co

Veteran executive previously led Abbott's global diagnostics organization Kim Popovits, interim chief executive officer, to resume role as Director on the Board of Talis MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced the appointment of Brian Blaser to President, Chief Executive Officer and Director. Kim Popovits, currently serving as Interim Chief Executive Officer, will resume her role as Director on the Board of Talis. These changes will be effective Decembe

MENLO PARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that effective immediately Brian Coe has stepped down as President, CEO and Director and will continue to work with the company as an advisor. The company also announced that Kim Popovits has been appointed as interim CEO and will lead the search efforts to hire the Company's next President and CEO. Ms. Popovits is the former Chairman of the Board, President and Chief Executive Officer of Genomic Health. Under her leadership Genomic Health became the world's le

MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the appointment of Jeryl “Jeri” Hilleman to its Board of Directors. Ms. Hilleman will serve as Chair of the Audit Committee. “We welcome Jeri to our Board and look forward to benefitting from her public company leadership as a chief financial officer and corporate director at multiple life science companies,” said Brian Coe, Chief Executive Officer of Talis. “Jeri’s experience and guidance will be instrumental as we continue to scale our business in prepara

15-12G - Talis Biomedical Corp (0001584751) (Filer)

25-NSE - Talis Biomedical Corp (0001584751) (Subject)

8-K - Talis Biomedical Corp (0001584751) (Filer)

S-8 POS - Talis Biomedical Corp (0001584751) (Filer)

S-8 POS - Talis Biomedical Corp (0001584751) (Filer)

S-8 POS - Talis Biomedical Corp (0001584751) (Filer)

S-8 POS - Talis Biomedical Corp (0001584751) (Filer)

8-K - Talis Biomedical Corp (0001584751) (Filer)

8-K/A - Talis Biomedical Corp (0001584751) (Filer)

8-K - Talis Biomedical Corp (0001584751) (Filer)